...develop a bacterial virulence inhibitor candidate targeting drug resistant Gram-negative bacteria including Pseudomonas aeruginosa from Microbiotix's...
...Centre will provide up to $1.1 million in technical support and project funding. In March, Microbiotix...
...clinic. The AMR Centre provided funding to CARB-X (see BioCentury Innovations, Oct. 6, 2016 ). Microbiotix Inc....

...Therapeutics Inc. announced the close of its series A round this week. Oppilotech Ltd. and Microbiotix Inc....
...for multidrug-resistance infections, including A. baumannii and Enterobacteriaceae $469 million; $4 million Phase I 1998 Microbiotix Inc....

...agents. At least three - AstraZeneca plc 's MedImmune LLC unit, KaloBios Pharmaceuticals Inc. and Microbiotix Inc....
...agreement in 2014. KaloBios continues to seek a partner to advance KB001-A for other indications. Microbiotix...
...Mentioned AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Debiopharm Group, Lausanne, Switzerland MedImmune LLC, Gaithersburg, Md. Microbiotix Inc....

...lead molecule. SciBX 7(8); doi:10.1038/scibx.2014.228 Published online Feb. 27, 2014 Patent application filed; licensed to Microbiotix Inc....

...Worcester, Mass. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Business: Infectious Merck granted Microbiotix...

...Merck & Co. Inc. (NYSE:MRK) granted Microbiotix Inc. (Worcester, Mass.) exclusive, worldwide rights to two non-nucleoside HCV...

...$1.7 7 ND MacroGenics Inc. $1.7 7 $126.6 Celldex Therapeutics Inc. (NASDAQ:CLDX) $1.7 7 $95.8 Microbiotix Inc....

...VP of IP and legal affairs, formerly co-founder, COO and VP of business development for Microbiotix Inc....

...relates to the company's MBX 300 oral compound in preclinical testing to treat RSV infection. Microbiotix Inc....

...Group plc's CADx Medical Systems subsidiary; he replaces A. Kirk Field, who becomes chairman of Microbiotix's...